CXC Chemokines and HIV Pathogenesis
CXC Chemokines and HIV Pathogenesis
批准号:
6839891
负责人:
David Michael Markovitz
金额:
$34.43万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-30 至 2005-04-14
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Replication of the Human Immunodeficiency Virus type 1 (HIV-1) is regulated by interactions with human cellular proteins. Among the cellular factors that influence both viral replication and pathogenesis are the cytokines. Chemokines, a subfamily of the cytokines, and their receptors have been shown to be important in HIV pathogenesis. Our group recently found that production of two CXC chemokines, Interleukin-8 (IL-8) and Growth-Regulated Oncogene-alpha (GRO-alpha), is markedly stimulated following exposure of monocyte-derived macrophages (MDM) to HIV, consistent with our observation that IL-8 expression in the lymphatics of HIV-infected patients correlates with viral load. We have further demonstrated that GRO-alpha and IL-8 production is stimulated by the interaction of the viral envelope protein gpl20 and the CXCR4 receptor. IL-8 and GRO-alpha then feed back and stimulate HIV-1 replication in both MDM and lymphocytes, likely by increasing viral entry. By blocking the action of these chemokines or their receptors, CXCR1 and CXCR2, HIV-1 replication is inhibited. As agents that block the function of IL-8 and GRO-alpha have been developed to treat inflammatory diseases, it would appear that this autocrine/paracrine loop is a potential target for HIV therapeutics.
We now propose to examine the correlation between clinical status and the ability of HIV isolates to induce production of IL-8 and GRO-alpha. We will also assess the correlation between clinical status and the response of HIV isolates to IL-8 and GRO-alpha. These studies will test the hypothesis that increased production of IL-8 and GRO-alpha is associated with more advanced disease. We will also define the molecular-level events by which HIV induces the production of these two chemokines, testing the hypothesis that gp 120 engagement of CXCR4 stimulates the activity of PKC and NF-kB, which leads to increased transcription and expression of IL-8 and GRO-alpha. We will also detail the mechanism(s) by which IL-8 and GRO-(x augment HIV replication, working under the hypothesis that these chemokines increase viral entry. A mechanistic understanding of the molecular interplay between IL-8, GRO-alpha, and their receptors could lead to the development of new approaches to the treatment of HIV-infected patients.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/bi1004365
发表时间:
2010-08-24
期刊:
BIOCHEMISTRY
影响因子:
2.9
作者:
[Fahrer, Joerg, Popp, Oliver, Malanga, Maria, Beneke, Sascha, Markovitz, David M., Ferrando-May, Elisa, Buerkle, Alexander, Kappes, Ferdinand]
通讯作者:
Kappes, Ferdinand
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
-
批准号:10629566
-
项目类别:
-
资助金额:$72.82万
-
财政年份:2023
-
负责人:David Michael Markovitz
-
依托单位:
DEK and TNF inhibitors in juvenile arthritis
-
批准号:8311059
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
Replication of Human Endogenous Retroviruses in Modern Humans
-
批准号:8318290
-
项目类别:
-
资助金额:$123.18万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
Replication of Human Endogenous Retroviruses in Modern Humans
-
批准号:7762721
-
项目类别:
-
资助金额:$143.53万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
DEK and TNF inhibitors in juvenile arthritis
-
批准号:8130630
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
DEK and TNF inhibitors in juvenile arthritis
-
批准号:7835950
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
DEK and TNF inhibitors in juvenile arthritis
-
批准号:7938774
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
Replication of Human Endogenous Retroviruses in Modern Humans
-
批准号:8119694
-
项目类别:
-
资助金额:$124.02万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
Replication of Human Endogenous Retroviruses in Modern Humans
-
批准号:8550159
-
项目类别:
-
资助金额:$8.26万
-
财政年份:2009
-
负责人:David Michael Markovitz
-
依托单位:
CXC Chemokines and HIV Pathogenesis
-
批准号:7160544
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2005
-
负责人:David Michael Markovitz
-
依托单位:
CXC Chemokines and HIV Pathogenesis
-
批准号:6946547
-
项目类别:
-
资助金额:$18.17万
-
财政年份:2005
-
负责人:David Michael Markovitz
-
依托单位:
CXC Chemokines and HIV Pathogenesis
-
批准号:7332237
-
项目类别:
-
资助金额:$35.58万
-
财政年份:2005
-
负责人:David Michael Markovitz
-
依托单位:
CXC Chemokines and HIV Pathogenesis
-
批准号:7555925
-
项目类别:
-
资助金额:$35.58万
-
财政年份:2005
-
负责人:David Michael Markovitz
-
依托单位:
CXC Chemokines and HIV Pathogenesis
-
批准号:7050061
-
项目类别:
-
资助金额:$37.35万
-
财政年份:2005
-
负责人:David Michael Markovitz
-
依托单位:
C-X-C Chemokines and Kaposi's Sarcoma
-
批准号:6758555
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2001
-
负责人:David Michael Markovitz
-
依托单位:
C-X-C Chemokines and Kaposi's Sarcoma
-
批准号:6908120
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2001
-
负责人:David Michael Markovitz
-
依托单位:
C-X-C Chemokines and Kaposi's Sarcoma
-
批准号:6608129
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2001
-
负责人:David Michael Markovitz
-
依托单位:
C-X-C Chemokines and Kaposi's Sarcoma
-
批准号:6537696
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2001
-
负责人:David Michael Markovitz
-
依托单位:
C-X-C Chemokines and Kaposi's Sarcoma
-
批准号:6346724
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2001
-
负责人:David Michael Markovitz
-
依托单位:
CELLULAR FACTORS INVOLVED IN HIV GENE EXPRESSION
-
批准号:6274727
-
项目类别:
-
资助金额:$2.15万
-
财政年份:1997
-
负责人:David Michael Markovitz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
发展基因编码的荧光探针揭示趋化因子CXCL10的时空动态及其调控机制
-
批准号:32371150
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:井淼
-
依托单位:
SDF-1/CXCR4信号通路在NMO-IgG介导的炎性脱髓鞘视神经炎中促进髓鞘修复的作用及机制研究
-
批准号:81900849
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2019
-
负责人:康皓
-
依托单位:
Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
-
批准号:81660467
-
项目类别:地区科学基金项目
-
资助金额:39.0万元
-
批准年份:2016
-
负责人:石超
-
依托单位:
间充质干细胞对异基因T细胞体内趋化影响机制的研究
-
批准号:81070448
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2010
-
负责人:任汉云
-
依托单位:
趋化因子及其受体介导的血源性干/祖细胞及血管内皮细胞在新生血管性眼病中免疫病理机制及干预
-
批准号:30972712
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:陆培荣
-
依托单位:
趋化因子及其受体与新生血管性眼病的形成机制及干预研究
-
批准号:30771978
-
项目类别:面上项目
-
资助金额:8.0万元
-
批准年份:2007
-
负责人:陆培荣
-
依托单位:
趋化因子及其受体与肝癌的发生发展
-
批准号:30572120
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2005
-
负责人:陆培荣
-
依托单位:
CKLF1在哮喘气道上皮损伤及重塑中的作用
-
批准号:30370622
-
项目类别:面上项目
-
资助金额:19.0万元
-
批准年份:2003
-
负责人:谭亚夏
-
依托单位: